Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies.
about
Crystal structure of the tyrosine kinase domain of the hepatocyte growth factor receptor c-Met and its complex with the microbial alkaloid K-252aThe establishment and characterization of the first canine hepatocellular carcinoma cell line, which resembles human oncogenic expression patternsTargeting cancer with kinase inhibitorsGenomic screening of fibroblast growth-factor receptor 2 reveals a wide spectrum of mutations in patients with syndromic craniosynostosisConformational changes in protein loops and helices induced by post-translational phosphorylation.Computational modeling of structurally conserved cancer mutations in the RET and MET kinases: the impact on protein structure, dynamics, and stability.Sequence and structure signatures of cancer mutation hotspots in protein kinasesHereditary leiomyomatosis and renal cell carcinoma.Cancer driver mutations in protein kinase genesThe Hepatocyte Growth Factor Receptor: Structure, Function and Pharmacological Targeting in CancerDysregulation of Met receptor tyrosine kinase activity in invasive tumorsA Drosophila model of multiple endocrine neoplasia type 2.Spectrum of diverse genomic alterations define non-clear cell renal carcinoma subtypes.Targeting the HGF/Met signalling pathway in cancer.Genetic counseling in renal masses.Targeting the Met signaling pathway in renal cancer.Inhibition of ligand-independent constitutive activation of the Met oncogenic receptor by the engineered chemically-modified antibody DN30.Met-induced membrane blebbing leads to amoeboid cell motility and invasion.The D816V mutation of c-Kit circumvents a requirement for Src family kinases in c-Kit signal transduction.Inhibitory effect of c-Met mutants on the formation of branching tubules by a porcine aortic endothelial cell line.Homology modeling and SAR analysis of Schistosoma japonicum cathepsin D (SjCD) with statin inhibitors identify a unique active site steric barrier with potential for the design of specific inhibitors.
P2860
Q24647566-AE1F0BC2-66A6-4DEF-B23F-73E612C7F213Q24803160-0B7E6D1E-77C1-4EB9-AF14-966E3D1CF798Q26865765-3A343593-C560-4605-9819-DC22249E2B40Q28344714-8DA67AB1-725E-4B91-903D-B17E797A3C4AQ28469001-E2D11F06-0DDC-4AF0-9270-643EBF630F1DQ30374663-B30CDFB2-E8C2-4094-9B74-DDD9B1EEEAFBQ33510934-0E54965C-38B5-43C0-8AD6-D3DBFC04F398Q33817755-DD25E08A-F7FC-4C76-A04A-8354D78DED14Q34002709-D9E4FB3D-8F9E-4605-BBA7-B8F72CE6A5F1Q34141913-9DBB9922-DEC1-478B-9246-49173BDD408AQ34584046-DB263281-A245-40BE-9FAB-3E917A0FBE54Q34589821-5B0563B4-EA8B-459E-9BFC-80CCE357920AQ35810625-C09CA335-FE76-48DE-B8A7-3E92E1B133AEQ36142604-C540FDD5-7E42-427E-833D-192247EB15CFQ36969087-6B5BCDBF-644D-406F-9DF3-AAD1A3785BEFQ37331862-14024F86-7786-42FE-990B-C8588C45E5A6Q38859217-B67E38AA-3E00-45A0-A7D8-614387D15336Q39153274-D128B684-E2E3-4E1A-A398-009E7DDC631DQ39876378-79FFB0BD-D527-4050-8F79-E0968261568EQ40221705-60D5F7C7-30D7-479F-9C80-40C603A96A70Q46151927-3108D8BD-9FA5-4B01-BEBE-76F7AFA0CE0C
P2860
Structural basis of oncogenic activation caused by point mutations in the kinase domain of the MET proto-oncogene: modeling studies.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
2001年论文
@zh
2001年论文
@zh-cn
name
Structural basis of oncogenic ...... to-oncogene: modeling studies.
@en
Structural basis of oncogenic ...... to-oncogene: modeling studies.
@nl
type
label
Structural basis of oncogenic ...... to-oncogene: modeling studies.
@en
Structural basis of oncogenic ...... to-oncogene: modeling studies.
@nl
prefLabel
Structural basis of oncogenic ...... to-oncogene: modeling studies.
@en
Structural basis of oncogenic ...... to-oncogene: modeling studies.
@nl
P2093
P2860
P356
P1433
P1476
Structural basis of oncogenic ...... to-oncogene: modeling studies.
@en
P2093
P2860
P356
10.1002/PROT.1069
P407
P577
2001-07-01T00:00:00Z